查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1360339

脂质体给药市场 - 2023-2031 年全球产业分析、规模、份额、成长、趋势与预测

Liposome Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

脂质体药物传输市场 - 报告范围

TMR 关于全球脂质体药物递送市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球脂质体药物递送的收入2017-2031年期间的市场，考虑2023年为基准年，2031年为预测年。报告也提供了2023年至2031年全球脂质体给药市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解脂质体药物传输市场。

市场概况
2023年市场价值 47 亿美元
2031 年市场价值 100 亿美元
复合年增长率 8.5%

该报告深入探讨了全球脂质体给药市场的竞争格局。全球脂质体药物传输市场的主要参与者已经确定，并且每个参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球脂质体药物输送市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 技术进步
  • 概述：系统
  • 监管场景
  • COVID-19 大流行对产业的影响（价值炼和短期/中期/长期影响）

第 6 章：全球市场分析与预测：依脂质体结构

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依脂质体结构，2017-2031
    • 单层脂质体
      • 小的
      • 大的
    • 多层脂质体
    • 其他的
  • 市场吸引力分析：依脂质体结构

第 7 章：全球市场分析与预测：依产品分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按产品，2017-2031
    • 脂质体阿霉素
    • 脂质体紫杉醇
    • 脂质体两性霉素B
    • 其他的
  • 市场吸引力分析：按产品

第 8 章：全球市场分析与预测：依技术分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依技术分类，2017-2031
    • 隐形脂质体技术
    • 非聚乙二醇化脂质体技术
    • DepoFoam 脂质体技术
    • 溶血脂热敏脂质体技术
  • 市场吸引力分析：依技术分类

第 9 章：全球市场分析与预测：按应用分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依应用分类，2017-2031
    • 真菌病
    • 癌症治疗
    • 疼痛管理
    • 病毒疫苗
    • 光动力疗法
    • 其他的
  • 市场吸引力分析：按应用

第 10 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2017-2031
    • 医院
    • 专科中心
    • 门诊手术中心
    • 其他的
  • 市场吸引力分析：按最终用户

第 11 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 12 章：北美市场分析与预测

第 13 章：欧洲市场分析与预测

第 14 章：亚太市场分析与预测

第 15 章：拉丁美洲市场分析与预测

第 16 章：中东和非洲市场分析与预测

第17章：竞争格局

  • 市场参与者-竞争矩阵：依公司层级与规模划分
  • 市占率分析：依公司划分，2021 年
  • 公司简介
    • Johnson & Johnson Services, Inc.
    • Gilead Sciences, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Janssen Pharmaceuticals, Inc.
    • CELSION Corporation
    • Abbott
    • Ipsen Pharma
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: TMRGL28571

Liposome Drug Delivery Market - Scope of Report

TMR's report on the global liposome drug delivery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global liposome drug delivery market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global liposome drug delivery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the liposome drug delivery market.

Market Snapshot
Market Value in 2023US$ 4.7 Bn
Market Value in 2031US$ 10 Bn
CAGR8.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global liposome drug delivery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global liposome drug delivery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global liposome drug delivery market.

The report delves into the competitive landscape of the global liposome drug delivery market. Key players operating in the global liposome drug delivery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global liposome drug delivery market profiled in this report.

Key Questions Answered in Global Liposome Drug Delivery Market Report:

  • What is the sales/revenue generated by liposome drug delivery across all regions during the forecast period?
  • What are the opportunities in the global liposome drug delivery market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Liposome Drug Delivery Market - Research Objectives and Research Approach

The comprehensive report on the global liposome drug delivery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global liposome drug delivery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global liposome drug delivery market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Liposome Drug Delivery Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Liposome Drug Delivery Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Overview: Liposome Drug delivery Systems
  • 5.3. Regulatory Scenario
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Liposome Drug Delivery Market Analysis and Forecast, by Liposome Structure

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Liposome Structure, 2017-2031
    • 6.3.1. Unilamellar Liposomes
      • 6.3.1.1. Small
      • 6.3.1.2. Large
    • 6.3.2. Multilamellar liposomes
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Liposome Structure

7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Product, 2017-2031
    • 7.3.1. Liposomal Doxorubicin
    • 7.3.2. Liposomal Paclitaxel
    • 7.3.3. Liposomal Amphotericin B
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Product

8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Technology, 2017-2031
    • 8.3.1. Stealth Liposome Technology
    • 8.3.2. Non PEGylated Liposome Technology
    • 8.3.3. DepoFoam Liposome Technology
    • 8.3.4. Lysolipid Thermally Sensitive Liposome Technology
  • 8.4. Market Attractiveness Analysis, by Technology

9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Application, 2017-2031
    • 9.3.1. Fungal Diseases
    • 9.3.2. Cancer Therapy
    • 9.3.3. Pain Management
    • 9.3.4. Viral Vaccines
    • 9.3.5. Photodynamic Therapy
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis, by Application

10. Global Liposome Drug Delivery Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Hospitals
    • 10.3.2. Specialty Centers
    • 10.3.3. Ambulatory Surgical Centers
    • 10.3.4. Others
  • 10.4. Market Attractiveness Analysis, by End-user

11. Global Liposome Drug Delivery Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Liposome Drug Delivery Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Liposome Structure, 2017-2031
    • 12.2.1. Unilamellar Liposomes
      • 12.2.1.1. Small
      • 12.2.1.2. Large
    • 12.2.2. Multilamellar liposomes
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Product, 2017-2031
    • 12.3.1. Liposomal Doxorubicin
    • 12.3.2. Liposomal Paclitaxel
    • 12.3.3. Liposomal Amphotericin B
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. Stealth Liposome Technology
    • 12.4.2. Non PEGylated Liposome Technology
    • 12.4.3. DepoFoam Liposome Technology
    • 12.4.4. Lysolipid Thermally Sensitive Liposome Technology
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Fungal Diseases
    • 12.5.2. Cancer Therapy
    • 12.5.3. Pain Management
    • 12.5.4. Viral Vaccines
    • 12.5.5. Photodynamic Therapy
    • 12.5.6. Others
  • 12.6. Market Value Forecast, by End-user, 2017-2031
    • 12.6.1. Hospitals
    • 12.6.2. Specialty Centers
    • 12.6.3. Ambulatory Surgical Centers
    • 12.6.4. Others
  • 12.7. Market Value Forecast, by Country, 2017-2031
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Liposome Structure
    • 12.8.2. By Product
    • 12.8.3. By Technology
    • 12.8.4. By Application
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Liposome Drug Delivery Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Liposome Structure, 2017-2031
    • 13.2.1. Unilamellar Liposomes
      • 13.2.1.1. Small
      • 13.2.1.2. Large
    • 13.2.2. Multilamellar liposomes
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Product, 2017-2031
    • 13.3.1. Liposomal Doxorubicin
    • 13.3.2. Liposomal Paclitaxel
    • 13.3.3. Liposomal Amphotericin B
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by Technology, 2017-2031
    • 13.4.1. Stealth Liposome Technology
    • 13.4.2. Non PEGylated Liposome Technology
    • 13.4.3. DepoFoam Liposome Technology
    • 13.4.4. Lysolipid Thermally Sensitive Liposome Technology
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Fungal Diseases
    • 13.5.2. Cancer Therapy
    • 13.5.3. Pain Management
    • 13.5.4. Viral Vaccines
    • 13.5.5. Photodynamic Therapy
    • 13.5.6. Others
  • 13.6. Market Value Forecast, by End-user, 2017-2031
    • 13.6.1. Hospitals
    • 13.6.2. Specialty Centers
    • 13.6.3. Ambulatory Surgical Centers
    • 13.6.4. Others
  • 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.7.1. Germany
    • 13.7.2. U.K
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Liposome Structure
    • 13.8.2. By Product
    • 13.8.3. By Technology
    • 13.8.4. By Application
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Liposome Structure, 2017-2031
    • 14.2.1. Unilamellar Liposomes
      • 14.2.1.1. Small
      • 14.2.1.2. Large
    • 14.2.2. Multilamellar liposomes
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Product, 2017-2031
    • 14.3.1. Liposomal Doxorubicin
    • 14.3.2. Liposomal Paclitaxel
    • 14.3.3. Liposomal Amphotericin B
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by Technology, 2017-2031
    • 14.4.1. Stealth Liposome Technology
    • 14.4.2. Non PEGylated Liposome Technology
    • 14.4.3. DepoFoam Liposome Technology
    • 14.4.4. Lysolipid Thermally Sensitive Liposome Technology
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Fungal Diseases
    • 14.5.2. Cancer Therapy
    • 14.5.3. Pain Management
    • 14.5.4. Viral Vaccines
    • 14.5.5. Photodynamic Therapy
    • 14.5.6. Others
  • 14.6. Market Value Forecast, by End-user, 2017-2031
    • 14.6.1. Hospitals
    • 14.6.2. Specialty Centers
    • 14.6.3. Ambulatory Surgical Centers
    • 14.6.4. Others
  • 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Liposome Structure
    • 14.8.2. By Product
    • 14.8.3. By Technology
    • 14.8.4. By Application
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Liposome Drug Delivery Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Liposome Structure, 2017-2031
    • 15.2.1. Unilamellar Liposomes
      • 15.2.1.1. Small
      • 15.2.1.2. Large
    • 15.2.2. Multilamellar liposomes
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Product, 2017-2031
    • 15.3.1. Liposomal Doxorubicin
    • 15.3.2. Liposomal Paclitaxel
    • 15.3.3. Liposomal Amphotericin B
    • 15.3.4. Others
  • 15.4. Market Value Forecast, by Technology, 2017-2031
    • 15.4.1. Stealth Liposome Technology
    • 15.4.2. Non PEGylated Liposome Technology
    • 15.4.3. DepoFoam Liposome Technology
    • 15.4.4. Lysolipid Thermally Sensitive Liposome Technology
  • 15.5. Market Value Forecast, by Application, 2017-2031
    • 15.5.1. Fungal Diseases
    • 15.5.2. Cancer Therapy
    • 15.5.3. Pain Management
    • 15.5.4. Viral Vaccines
    • 15.5.5. Photodynamic Therapy
    • 15.5.6. Others
  • 15.6. Market Value Forecast, by End-user, 2017-2031
    • 15.6.1. Hospitals
    • 15.6.2. Specialty Centers
    • 15.6.3. Ambulatory Surgical Centers
    • 15.6.4. Others
  • 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Liposome Structure
    • 15.8.2. By Product
    • 15.8.3. By Technology
    • 15.8.4. By Application
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Liposome Structure, 2017-2031
    • 16.2.1. Unilamellar Liposomes
      • 16.2.1.1. Small
      • 16.2.1.2. Large
    • 16.2.2. Multilamellar liposomes
    • 16.2.3. Others
  • 16.3. Market Value Forecast, by Product, 2017-2031
    • 16.3.1. Liposomal Doxorubicin
    • 16.3.2. Liposomal Paclitaxel
    • 16.3.3. Liposomal Amphotericin B
    • 16.3.4. Others
  • 16.4. Market Value Forecast, by Technology, 2017-2031
    • 16.4.1. Stealth Liposome Technology
    • 16.4.2. Non PEGylated Liposome Technology
    • 16.4.3. DepoFoam Liposome Technology
    • 16.4.4. Lysolipid Thermally Sensitive Liposome Technology
  • 16.5. Market Value Forecast, by Application, 2017-2031
    • 16.5.1. Fungal Diseases
    • 16.5.2. Cancer Therapy
    • 16.5.3. Pain Management
    • 16.5.4. Viral Vaccines
    • 16.5.5. Photodynamic Therapy
    • 16.5.6. Others
  • 16.6. Market Value Forecast, by End-user, 2017-2031
    • 16.6.1. Hospitals
    • 16.6.2. Specialty Centers
    • 16.6.3. Ambulatory Surgical Centers
    • 16.6.4. Others
  • 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & South Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Liposome Structure
    • 16.8.2. By Product
    • 16.8.3. By Technology
    • 16.8.4. By Application
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix, by tier and size of companies
  • 17.2. Market Share Analysis, by Company, 2021
  • 17.3. Company Profiles
    • 17.3.1. Johnson & Johnson Services, Inc.
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. Gilead Sciences, Inc.
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Sun Pharmaceutical Industries Ltd.
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Novartis AG
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Teva Pharmaceutical Industries Ltd
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Janssen Pharmaceuticals, Inc.
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. CELSION Corporation
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Abbott
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Ipsen Pharma
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. Spectrum Pharmaceuticals, Inc.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
    • 17.3.11. Takeda Pharmaceutical Company Limited
      • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.11.2. Product Portfolio
      • 17.3.11.3. Financial Overview
      • 17.3.11.4. SWOT Analysis
      • 17.3.11.5. Strategic Overview

List of Tables

  • Table 01: Pipeline Analysis - Liposome Drug Delivery Systems
  • Table 02: Clinically Marketed Liposome Drugs
  • Table 03: Regulations - Principle difference between U.S., EU and India
  • Table 04: Regulatory Scenario Assessment - Administrative Requirements
  • Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
  • Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
  • Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
  • Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
  • Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027
  • Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027
  • Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

List of Figures

  • Figure 01: Global Liposome Drug Delivery Market Snapshot
  • Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2022 and 2031
  • Figure 03: Therapeutic applications of liposomes in drug delivery
  • Figure 04: Advantages of liposome drug delivery system
  • Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017-2027
  • Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2022
  • Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2022
  • Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2022
  • Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2022
  • Figure 10: Regulatory Approval Process - U.S.
  • Figure 11: Regulatory Approval Process - Europe
  • Figure 12: Regulatory Approval Process - India
  • Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017-2027
  • Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017-2027
  • Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017-2027
  • Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017-2027
  • Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017-2027
  • Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017-2027
  • Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017-2027
  • Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017-2027
  • Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017-2027
  • Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017-2027
  • Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic therapy, 2017-2027
  • Figure 31: Global Liposome Drug Delivery Market - Regional Outlook
  • Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031
  • Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031
  • Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031